Hausa translation of DOI: 10.1101/2021.02.05.21250735
Yawancin cututtukan SARS-CoV-2 waɗanda ba a gano su ba suna kawo ƙalubale don bin diddigin ci gaban cutar da aiwatar da matakan sarrafawa a Kenya.
Mun ƙaddara yawan IgG zuwa SARS-CoV-2 a cikin ragowar samfuran jini daga uwayen da ke halartar ayyukan kula da mata masu juna biyu a asibitoci 2 na Kenya.
Mun yi amfani da ingantaccen IgG ELISA don furotin mai karuwa na SARS-CoV-2 kuma mun daidaita sakamakon don tantancewa da ƙayyadaddun bayanai.
A Asibitin Kasa na Kenyatta, Nairobi, yaduwa a watan Agusta 2020 ya kasance 49.9% (95% CI 42.7-58.0).
A cikin Asibitin gundumar Kilifi, cutar ta karu daga 1.3% (95% CI 0.04-4.7) a cikin Satumba zuwa 11.0% (95% CI 6.2-16.7) a cikin Nuwamba 2020.
An sami yaxuwar cutar ta SARS-CoV-2 da ba a lura da ita ba a sassan Nairobi da Lardunan Kilifi.
Masu bincike sun ba da rahoton cewa a cikin 2021, samfurori daga yawancin mata masu juna biyu a Kenya sun gwada ingancin kwayoyin rigakafin kwayar cutar da ke haifar da COVID-19.
Wannan yana nufin sun kamu da cutar a baya, ko kuma sun kamu da cutar a lokacin, amma yawancin waɗannan cututtukan ba a gano su ta sakamakon gwajin sarkar polimerase (PCR) ba.
Masu binciken sun ce mai yiwuwa COVID-19 ya zama ruwan dare a Kenya a lokacin.
Gabaɗaya, gwamnatoci suna buƙatar ingantaccen bayani game da mutane nawa za su iya kamuwa da cutar don sanya matakan sarrafawa da jinya.
A Kenya, mutane da yawa ba su je gwajin COVID-19 ba.
Wannan na iya zama saboda yawancin jama'ar matasa ne, kuma da yawa ba su da alamun bayyanar cutar ko kuma su nuna alamu masu sauqi.
Masana kimiyya sun ce auna yawan ƙwayoyin rigakafi ga SARS-CoV-2 hanya ɗaya ce ta kimanta adadin cututtukan.
Kwayoyin rigakafi sune takamaiman sunadaran da aka samar a cikin jiki don kare wata cuta, kuma kasancewarsu yana nufin bayyanar ko kamuwa da cuta a baya.
A cikin wannan binciken, masu bincike sun ƙaddara yawan ƙwayoyin rigakafin SARS-CoV-2 a cikin mata masu juna biyu a asibitoci 2 a Nairobi da Kilifi, Kenya.
Sun yi gwajin rigakafin SARS-CoV-2 a cikin samfuran jini daga matan.
Sun kwatanta adadin ingantattun samfuran da suka samu tare da adadin cututtukan da aka tabbatar ta hanyar PCR na SARS-CoV-2 da suka samu daga Ma'aikatar Lafiya na wurare iri ɗaya.
Masu binciken sun kuma sake nazarin bayanan kiwon lafiya kuma sun lura lokacin da aka tattara samfuran, da kuma shekarun su, wurin zama, kwanakin ciki da kasancewar ko rashin alamun COVID-19.
Sun gano cewa rabin samfuran a Nairobi sun gwada inganci don rigakafin SARS-CoV-2, kuma tsakanin 1.3% zuwa 10% a Kilifi.
Kwayoyin da aka tabbatar da PCR sun kasance ƙasa da 1% a duk sassan biyu, ma'ana cewa ba a ba da rahoton ainihin adadin cututtukan ba.
Sun kuma gano cewa kashi 7% kawai na matan sun ba da rahoton alamun COVID-19 masu alaƙa, ma'ana cewa yawancin cututtukan da ba su da alaƙa.
Masu binciken sun ba da shawarar cewa yana iya zama mafi kyau a yi amfani da gwajin rigakafin SARS-CoV-2 don ƙididdige ainihin adadin mutanen da suka kamu da cutar a Kenya.
Suna yin taka tsantsan duk da haka cewa sun yi amfani da bayanan marasa lafiya da ba a san su ba, don haka ba su iya kwatantawa da wasu kafofin don tabbatar da bincikensu ba.
Masu binciken sun kuma bayyana cewa ba su da bayanai kan asarar ƙwayoyin rigakafi, wanda ke da mahimmanci don ƙididdige adadin masu kamuwa da cuta.
Wannan binciken wani yanki ne na babban shiri don sa ido kan SARS-CoV-2 ta amfani da ƙwayoyin rigakafi a Kenya, kuma shirin KEMRI Wellcome Trust Research ne ya jagoranta.
Creative Commons Attribution 4.0 International License (CC-BY 4.0)
